Tags

Type your tag names separated by a space and hit enter

Simplified flow cytometric immunophenotyping panel for multiple myeloma, CD56/CD19/CD138(CD38)/CD45, to differentiate neoplastic myeloma cells from reactive plasma cells.
Korean J Hematol. 2012 Dec; 47(4):260-6.KJ

Abstract

BACKGROUND

Flow cytometric immunophenotyping has been used to identify neoplastic plasma cell populations in patients with multiple myeloma (MM). Previous reports have described the use of several antigens, including CD38, CD138, CD56, CD117, CD52, CD19 and CD45, to distinguish distinct populations of plasma cells. The aim of this study was to evaluate a simplified immunophenotyping panel for MM analysis.

METHODS

A total of 70 patients were enrolled in the study, 62 of which were newly diagnosed with MM (untreated), whereas the remaining 8 were undergoing bone marrow assessment as part of follow-up after treatment (treated). Treated cases included 3 patients with relapse and 5 patients with persistence of MM. Multiparametric flow cytometric immunophenotyping was performed using monoclonal antibodies against CD56, CD19, CD138 (CD38), and CD45.

RESULTS

In differential counts, plasma cells in bone marrow (BM) accounted for 3.6-93.2% of the total nucleated cell count. The positive expression rates of CD56, CD19, CD138, and CD45 in neoplastic myeloma cells were 83.9%, 0%, 98.4%, and 37.1%, respectively, among the 62 untreated cases, and 75.0%, 0%, 87.5%, and 37.5%, respectively, among the 8 treated cases. CD19 expression of neoplastic plasma cells was negative in both untreated and treated cases.

CONCLUSION

The simplified immunophenotyping panel, CD56/CD19/CD138(CD38)/CD45, is useful for distinguishing neoplastic myeloma cells from reactive plasma cells in clinical practice. In addition, CD19 represents the most valuable antigen for identifying neoplastic myeloma cells in patients with MM.

Authors+Show Affiliations

Department of Laboratory Medicine, University of Ulsan College of Medicine and Asan Medical Center, Seoul, Korea.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

23320004

Citation

Jeong, Tae-Dong, et al. "Simplified Flow Cytometric Immunophenotyping Panel for Multiple Myeloma, CD56/CD19/CD138(CD38)/CD45, to Differentiate Neoplastic Myeloma Cells From Reactive Plasma Cells." The Korean Journal of Hematology, vol. 47, no. 4, 2012, pp. 260-6.
Jeong TD, Park CJ, Shim H, et al. Simplified flow cytometric immunophenotyping panel for multiple myeloma, CD56/CD19/CD138(CD38)/CD45, to differentiate neoplastic myeloma cells from reactive plasma cells. The Korean journal of hematology. 2012;47(4):260-6.
Jeong, T. D., Park, C. J., Shim, H., Jang, S., Chi, H. S., Yoon, D. H., Kim, D. Y., Lee, J. H., Lee, J. H., Suh, C., & Lee, K. H. (2012). Simplified flow cytometric immunophenotyping panel for multiple myeloma, CD56/CD19/CD138(CD38)/CD45, to differentiate neoplastic myeloma cells from reactive plasma cells. The Korean Journal of Hematology, 47(4), 260-6. https://doi.org/10.5045/kjh.2012.47.4.260
Jeong TD, et al. Simplified Flow Cytometric Immunophenotyping Panel for Multiple Myeloma, CD56/CD19/CD138(CD38)/CD45, to Differentiate Neoplastic Myeloma Cells From Reactive Plasma Cells. The Korean journal of hematology. 2012;47(4):260-6. PubMed PMID: 23320004.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Simplified flow cytometric immunophenotyping panel for multiple myeloma, CD56/CD19/CD138(CD38)/CD45, to differentiate neoplastic myeloma cells from reactive plasma cells. AU - Jeong,Tae-Dong, AU - Park,Chan-Jeoung, AU - Shim,Hyoeun, AU - Jang,Seongsoo, AU - Chi,Hyun-Sook, AU - Yoon,Dok Hyun, AU - Kim,Dae-Young, AU - Lee,Jung-Hee, AU - Lee,Je-Hwan, AU - Suh,Cheolwon, AU - Lee,Kyoo Hyung, Y1 - 2012/12/24/ PY - 2012/07/16/received PY - 2012/09/27/revised PY - 2012/11/06/accepted PY - 2013/1/16/entrez PY - 2013/1/16/pubmed PY - 2013/1/16/medline KW - CD19 negativity KW - Flow cytometry KW - Immunophenotyping KW - Multiple myeloma KW - Neoplastic plasma cells SP - 260 EP - 6 JF - The Korean journal of hematology VL - 47 IS - 4 N2 - BACKGROUND: Flow cytometric immunophenotyping has been used to identify neoplastic plasma cell populations in patients with multiple myeloma (MM). Previous reports have described the use of several antigens, including CD38, CD138, CD56, CD117, CD52, CD19 and CD45, to distinguish distinct populations of plasma cells. The aim of this study was to evaluate a simplified immunophenotyping panel for MM analysis. METHODS: A total of 70 patients were enrolled in the study, 62 of which were newly diagnosed with MM (untreated), whereas the remaining 8 were undergoing bone marrow assessment as part of follow-up after treatment (treated). Treated cases included 3 patients with relapse and 5 patients with persistence of MM. Multiparametric flow cytometric immunophenotyping was performed using monoclonal antibodies against CD56, CD19, CD138 (CD38), and CD45. RESULTS: In differential counts, plasma cells in bone marrow (BM) accounted for 3.6-93.2% of the total nucleated cell count. The positive expression rates of CD56, CD19, CD138, and CD45 in neoplastic myeloma cells were 83.9%, 0%, 98.4%, and 37.1%, respectively, among the 62 untreated cases, and 75.0%, 0%, 87.5%, and 37.5%, respectively, among the 8 treated cases. CD19 expression of neoplastic plasma cells was negative in both untreated and treated cases. CONCLUSION: The simplified immunophenotyping panel, CD56/CD19/CD138(CD38)/CD45, is useful for distinguishing neoplastic myeloma cells from reactive plasma cells in clinical practice. In addition, CD19 represents the most valuable antigen for identifying neoplastic myeloma cells in patients with MM. SN - 1738-7949 UR - https://www.unboundmedicine.com/medline/citation/23320004/Simplified_flow_cytometric_immunophenotyping_panel_for_multiple_myeloma_CD56/CD19/CD138_CD38_/CD45_to_differentiate_neoplastic_myeloma_cells_from_reactive_plasma_cells_ L2 - http://www.bloodresearch.or.kr/journal/search_index.php?vol=47&num=4&page=260 DB - PRIME DP - Unbound Medicine ER -
Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.